• 2222
• AMZN
• LLY
• META
• MSFT
• ORCL
• TSLA

Tech market values jump in September on Fed rate cuts, AI optimism

Tech companies saw significant market cap increases in September due to a Fed rate cut and AI enthusiasm, while Eli Lilly and Saudi Oil experienced declines.

• LLY

MBX Biosciences seeks up to $482.5 million valuation in US IPO

MBX Biosciences plans an IPO for up to $482.5 million, focusing on peptide therapies for obesity and endocrine disorders, amid growing investor interest in weight-loss drugs.

• AHR
• CMG
• DUOL
• LLY
• MAA
• MKC
• NOC
• NVR
• RNR
• RTX
• UBER

Uber, Eli Lilly and 9 other stocks are added to BofA's Top Picks list

Bank of America added 11 stocks to its top picks list, including Uber, Eli Lilly, and Chipotle, citing economic changes and individual strengths amid market volatility.

• LLY
• NVO
• SNY

How fake Ozempic batch numbers help criminal groups spread dangerous drugs

Drew from Texas bought fake Ozempic pens in Mexico, highlighting a larger issue of global drug counterfeiting prompting health concerns and market exploitation.

• LLY
• NVO

BioAge Labs Files for Proposed IPO

BioAge Labs files for IPO focusing on therapies for metabolic diseases like obesity, led by azelaprag. Trials with GLP-1R agonists planned for 2025.

• AMZN
• BRKa
• GOOGL
• LLY
• META
• NVDA
• TSLA

Tech market values fall on AI costs and recession fears; Eli Lilly, Berkshire gain

Major tech firms saw market value declines in August due to AI costs and recession fears, while Eli Lilly and Berkshire Hathaway had notable gains.

• LLY
• NVO

Wegovy reduces Covid-19 deaths and illness, study finds

Novo Nordisk's drug Wegovy may lower Covid-19 death rates, showing benefits beyond weight loss, as related to Covid severity and overall mortality, according to a large-scale study.

• HIMS
• LLY

Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound

Eli Lilly's new obesity medication Zepbound, priced significantly lower than competitors, has caused Hims & Hers Health shares to drop, intensifying market competition.

• LLY

Eli Lilly stock dips as single-dose Zepbound price is cut in half

Eli Lilly announced a price cut for Zepbound, its obesity drug, reducing costs significantly to improve patient access and respond to high demand.

• LLY
• NVO

Lilly launches vials of weight-loss drug Zepbound for as low as $399 a month